Belépés

NCT07446452Toboroz2. fázis

Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

A Phase II Clinical Study to Evaluate the Efficacy and Safety of Disitamab Vedotin in Combination With Bevacizumab in Patients With HER2-Low Metastatic Breast Cancer After Progression on Prior T-DXd Therapy

Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. márc. 3.

Rövid összefoglaló (regiszter, angolul)

This is a multicenter, single-arm, phase II clinical trial designed to evaluate the efficacy and safety of disitamab vedotin in combination with bevacizumab in patients with HER2-low advanced or metastatic breast cancer who have experienced disease progression following prior T-DXd therapy. Eligible patients must have HER2-low expression (IHC 1+ or 2+/FISH-) and have previously received T-DXd. Participants will receive RC48 (disitamab vedotin) plus bevacizumab according to the study protocol. Treatment-related adverse events will be closely monitored and managed, with severity graded according to CTCAE v5.0 criteria. Supportive care or dose adjustments will be implemented as necessary. The primary endpoint is objective response rate (ORR). Secondary endpoints include progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and duration of response (DOR), all of which will be evaluated by an independent review committee. Safety assessments will include the incidence, severity, management, and outcomes of adverse events. Patient-reported quality of life will be evaluated using the EORTC QLQ-C30 questionnaire at predefined intervals. In addition, this study will conduct exploratory multi-omics translational research to investigate the potential molecular mechanisms underlying treatment response and resistance, and to identify predictive biomarkers associated with clinical outcomes. The ultimate goal is to assess the therapeutic efficacy and safety of this regimen, and to develop predictive models that may help identify HER2-low patients most likely to benefit, thereby supporting precision and individualized treatment strategies.

Állapot (regiszter)
Toboroz
Fázis (regiszter)
2. fázis
Vizsgálattípus
Beavatkozással járó
Résztvevők száma
37 (tervezett)
Első benyújtás
2025. nov. 24.
Kezdés
2024. jan. 1.
Elsődleges befejezés
2026. dec. 6.
Fő szponzor
The First Affiliated Hospital with Nanjing Medical University
NCT-szám
NCT07446452

Mit vállalsz

  • Vizsgálat típusa: Beavatkozással járó · 2. fázis
  • Tervezett résztvevők: 37
  • 2024. jan. 1. és az elsődleges befejezés (2026. dec. 6.) között
  • 1 helyszín, 1 országban
  • Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket

A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.

Ki nem vehet részt

Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.

Korábbi kezelés

  • Clinically uncontrolled pleural effusion, ascites, or pericardial effusion requiring drainage within 2 weeks prior to enrollment.
  • Use of systemic immunosuppressive medications within 14 days prior to the first dose.
  • Allogeneic organ transplantation or hematopoietic stem cell transplantation (except corneal transplant).
  • Unresolved toxicities or complications from prior therapy that have not recovered to baseline or ≤Grade 1 (per CTCAE v5.0).
  • Receipt of a live vaccine within 30 days before Cycle 1 Day 1.

Más betegség

  • Uncontrolled comorbid conditions.
  • History or current evidence of interstitial lung disease (ILD) or non-infectious pneumonitis.
  • Known hypersensitivity to bevacizumab, disitamab vedotin, or any of their components or excipients.
  • Known human immunodeficiency virus (HIV) infection (HIV-1/2 antibody positive).
  • Untreated active hepatitis B infection.
  • Active hepatitis C virus (HCV) infection.
  • Any severe or uncontrolled systemic disease judged by the investigator to interfere with study participation or safety evaluation.
  • Gastrointestinal perforation or fistula, wound dehiscence requiring medical intervention, wound-healing complications, severe hemorrhage, arterial thrombotic events, or life-threatening (Grade 4) venous thromboembolism, including pulmonary embolism.

Egyéb

  • Clinically significant pulmonary comorbidities.
  • Spinal cord compression or clinically active central nervous system (CNS) metastases.
  • Pregnant or breastfeeding women.

Kiket keres a vizsgálat

  • Signed written informed consent prior to any study-related procedures.
  • Female or male participants aged 18 years or older.
  • Histologically or cytologically confirmed advanced or recurrent/metastatic HER2-low breast cancer (IHC 1+ or IHC 2+/ISH-).
  • Received at least two cycles of trastuzumab deruxtecan (T-DXd) during treatment for recurrent or metastatic disease.
  • At least one measurable lesion according to RECIST version 1.1. A lesion within a previous radiation field may be considered measurable if disease progression is confirmed at that site.
  • ECOG performance status 0-2.
  • Expected survival time \>3 months.
  • Left ventricular ejection fraction (LVEF) ≥50% by ECHO or MUGA within 4 weeks prior to the first dose.
  • Adequate organ function as determined by laboratory assessments per investigator's judgment.

Életkor a regiszterben: 18 év – 75 év · Nem: csak nők · Egészséges önkénteseket nem fogad

A teljes feltétellista: ClinicalTrials.gov

Helyszínek (1)

Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.

HelyszínVárosOrszágHelyszín állapota
The First Affiliated Hospital with Nanjing Medical University
Ennek a helyszínnek vagy a koordinátora? Erősítsd meg az állapotát		NanjingKínaToboroz

Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.